Refine
Has Fulltext
- yes (72)
Is part of the Bibliography
- yes (72)
Year of publication
Document Type
- Journal article (65)
- Preprint (4)
- Conference Proceeding (3)
Language
- English (72)
Keywords
- PET (17)
- prostate cancer (13)
- theranostics (13)
- positron emission tomography (11)
- CXCR4 (10)
- PET/CT (10)
- Positronen-Emissions-Tomografie (10)
- PSMA (9)
- multiple myeloma (8)
- neuroendocrine tumor (8)
Institute
- Klinik und Poliklinik für Nuklearmedizin (72) (remove)
Sonstige beteiligte Institutionen
Background
Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment.
Methods
To non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically proven MCC SSTR-PET was performed and compared to results of computed tomography (CT).
Results
SSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were up-staged due to SSTR-PET and patient management was changed in 3 patients (13%).
Conclusion
SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management.